For the 40% of American adults with obesity, glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, may offer hopebut the cost can put them out of reach for many patients
PlexusDx offers compounded Semaglutide Injection at $189/mo month-to-month, or from $149/mo on the 6-month plan, providing access to this evidence-based therapy without insurance requirements or membership fees
The availability of oral formulations addresses patient preferences for non-injectable medications while the entry of additional manufacturers beyond the current duopoly is expected to improve supply availability and create pricing competition that will facilitate broader access
Continuing to push through a genuine negative reaction with the hope its just purging is one of the most common routes to the kind of barrier damage that takes months to fully resolve
And it's the same thing with Medicare and Medicare Advantage healthcare plans
Ann Emerg Med 2002, 39: 616-621